Efficacy and safety of artesunate–amodiaquine and artemether–lumefantrine and prevalence of molecular markers associated with resistance, Guinea: an open-label two-arm randomised controlled trial
Reference:
Malaria Journal 2020 19:223, 24 June 2020
Anti-malarial resistance is a threat to recent gains in malaria control. This study aimed to assess the efficacy and safety of artesunate–amodiaquine (ASAQ) and artemether–lumefantrine (AL) in the management of uncomplicated malaria and to measure the prevalence of molecular markers of resistance of Plasmodium falciparum in sentinel sites in Maferinyah and Labé Health Districts in Guinea in 2016.
This week WHO reiterated the fragility of the gains the world has made over the last decade through intense deployment of vector control in the fight against malaria. Reuters published an online article on the matter titled '
Sometimes you come across articles that blow your mind. You read them and feel your heartbeat increasing. Each sentence you finish makes you wonder more what is going on here. What the politics are, who's really behind it, and what the goal of it is....
Most of us that have worked in the field of malaria for a few decades have gone through periods where we suddenly noticed changes in drug policy. When chloroquine was replaced by sulfadoxine-pyremethamine as a first-line drug, later to be replaced by artemisinin combination therapies (ACTs).